Smart Immune announces participation in leading scientific conferences

‍

The research and development as well as pharmaceutical development teams of Smart Immune are scheduled to present at the following congresses.

‍

 8^thCAR-TCR Summit, August 30 at 1:30 pm, Boston

Presentation by our Chief Scientific Officer, Olivier Negre

“CAR ProTcell, toward new generation allogeneic CAR-T cell”

‍

‍ISCT North America Regional Meeting, September 9,8 am, Houston

Roundtable with our R&D Director Shabi Soheili, Ph.D.

"How to optimize toxicity and relapse control after HCT"

4^thInternational Conference on Lymphocyte Engineering ICLE, Sept 12-14, Munich

Two posters are to be presented by Juliette Paillet,Ph.D., research scientist, and Marta Martin Corredera, a Ph.D. student at Smart Immune and Imagine Institute

allogeneic"ProTcell: ex-vivo generated T lymphoid progenitors exhibit thymic regenerative properties" and "Feeder-free culture system for ex via generation of large numbers of NK and CAR-NK cells from hematopoietic stem and progenitor cells."

Advanced Therapies Europe, September 5-7, Estoril

Presentation by our Chief Scientific Officer, Olivier Negre

“Designing next-generation allogeneic T-cell therapies empowered by the thymus

- Producing large numbers of clinical grade T-cell progenitors through a proprietary ex vivo lymphoid niche in 7 days

- Harnessing the potential of T-cell progenitors to generate innovative allogeneic cellular immunotherapy products

- Taking advantage of the thymus to avoid graft vs. host disease in the context of allogeneic T-cell therapy”

ESGCT 30th Annual congress, 24-27 October, Brussels

"CAR ProTcell, towards well-tolerated and persistent off-the-shelf allogeneic CAR-T cells"

Presentation by our Chief Scientific Officer, Olivier Negre

SESSION 2a: Genome editing for cancer immunotherapy Tuesday, October 24th, 5 to 7 pm

‍

CGT Manufacturing Congress, Cell 2023, November 7-8, London

Presentation by our Chief Technical Officer, Pierre Heimendinger

"ProTcell: T Cell Progenitor based therapy, from Clinical grade manufacturing Process to Phase III Readiness"

‍

Cell and gene therapy, manufacturing, commercialisation, 4-7 Dec 2023

Presentation by our Chief Technical Officer, Pierre Heimendinger

"ProTcell: Manufacturing Challenges of T Cell Progenitor Based Therapy, A Phase III Strategy"

Dec 05, 14:15

‍

‍

‍